NCT03635892进行中（未招募）2 期
A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
- 试验地点
- 7
- 主要终点
- objective response rate
研究概览
简要总结
The purpose of this study is to compare any good and bad effects of using a combination of nivolumab (Opdivo®) and cabozantinib (Cabometyx®) in people with metastatic kidney cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated IRB-approved Informed Consent Form
- •Pathologic or histologically confirmed unresectable advanced or metastatic nccRCC
- •0 or 1 prior systemic therapies, including treatment in the adjuvant setting
- •Availability of a representative formalin fixed, paraffin embedded tumor specimen or fresh frozen tissue specimen that enables the definitive diagnosis of RCC, accompanied by an associated pathology report. Specimens can be collected by surgical resection or biopsy of the primary tumor or biopsy or resection of a metastatic lesion.
- •Measurable disease, as defined by RECIST 1.1
- •Age ≥18 years
- •Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless adverse events (AE(s)) are clinically nonsignificant and/or stable on supportive therapy.
- •Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment:
- •ANC ≥ 1500 cells/μL (without granulocyte colony stimulating factor support within 2 weeks prior to Cycle 1, Day 1)
- •WBC counts ≥ 2500/μL and ≤ 15,000/μL without G-CSF
- •Lymphocyte count ≥ 500/μL
- •Platelet count ≥100,000/μL (without transfusion within 2 weeks prior to Cycle 1, Day 1)
- •Hemoglobin ≥9.0 g/dL (without transfusion within 2 weeks prior to Cycle 1, Day 1)
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN if patient has documented bone metastases.
- •Serum bilirubin ≤ 1.5 x ULN . Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled.
- •Serum albumin ≥ 2.8 g/dl
- •Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled.
- •INR and aPTT ≤ 1.3 x ULN • within 14 days of first dose of study treatment.This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
- •Creatinine ≤ 2.0 x ULN or Calculated Creatinine clearance ≥ 30mL/min
- •For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of ≥ 1% per year
- •Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)
- •Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 5 months after the last dose of study treatment for females and 7 months for males.
- •Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who are surgically sterile as described above).
- •However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.
- •Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
排除标准
- •Prior treatment with an immunotherapy agent including high dose IL-2, anti-CTLA-4, anti-PD1, and anti-PD-L1 agents
- •Prior treatment with cabozantinib for non-clear cell RCC
- •Receipt of any type of small molecule kinase inhibitor within 2 weeks of treatment.
- •Receipt of any type of anti-cancer antibody, cytotoxic anticancer therapy, or any other investigational agents within 4 weeks of treatment start
- •Known malignancies of the brain or spinal cord or leptomeningeal disease
- •Patients requiring pain medication must be on a stable regimen at study entry
- •Systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroids > 10 mg daily prednisone equivalents are allowed in the absence of autoimmune disease
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
- •Uncontrolled hypercalcemia (≥ 1.5 mmol/L ionized calcium or Ca ≥ 12 mg/dL or corrected serum calcium ≥ ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
- •Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy
- •Pregnant and lactating women History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
- •History of HIV infection
- •Patients with active or chronic hepatitis B or hepatitis C infection
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 6 months, unstable arrhythmias, unstable angina, or EF < 50%
- •Uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment
- •Patients with known coronary artery disease, congestive heart failure not meeting the above criteria must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
- •Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before first dose and from minor surgery (eg, simple excision, biopsy, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible
- •History of stroke or transient ischemic attack within 6 months prior to Cycle 1, Day 1
- •Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1
- •Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
- •Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding
- •Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
- •Patients with a history of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to study enrollment
- •Other clinically significant disorders that would preclude safe study participation
- •Serious non-healing wound/ulcer/bone fracture
- •Uncompensated/symptomatic hypothyroidism
- •Moderate to severe hepatic impairment (Child-Pugh B or C)
- •Corrected QT interval calculated by the Frederica formula (QTcF) > 500 ms per elFectrocardiogram (ECG) within 28 days before first dose of study treatment Note: If a single ECG shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility
- •Inability to swallow tablets or capsules
- •Previously identified allergy or hypersensitivity to components of the study treatment formulations
- •Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
- •Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:
- •Low-dose aspirin for cardio protection (per local applicable guidelines) is permitted
- •Low-dose low molecular weight heparins (LMWH) are permitted
- •Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban allowed in subjects without known brain metastases who are on a stable dose of LMWH for at least 1 week before first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
- •Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose
- •Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation
- •The subject has tumor invading or encasing any major blood vessels
- •The subject has evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib
- •Uncontrolled hypertension (>150 mmHg systolic or > 100 mmHg diastolic despite optimal antihypertensive treatment)
- •Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible. Radiation for palliation is allowable on study.
研究组 & 干预措施
Cohort 1: Unclassified, papillary, and HL RCC
Experimental
Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
干预措施: cabozantinib (Drug)
Cohort 1: Unclassified, papillary, and HL RCC
Experimental
Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
干预措施: nivolumab (Drug)
Cohort 2: Chromophobe RCC
Experimental
Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
干预措施: cabozantinib (Drug)
Cohort 2: Chromophobe RCC
Experimental
Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
干预措施: nivolumab (Drug)
Cohort 3: Unclassified, papillary, and HL RCC
Experimental
Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
干预措施: cabozantinib (Drug)
Cohort 3: Unclassified, papillary, and HL RCC
Experimental
Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
干预措施: nivolumab (Drug)
Cohort 4: Unclassified, papillary, and HL RCC
Experimental
Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
干预措施: cabozantinib (Drug)
Cohort 4: Unclassified, papillary, and HL RCC
Experimental
Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
干预措施: nivolumab (Drug)
结局指标
主要结局
objective response rate
时间窗: 2 years
per RECIST v1.1
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
进行中（未招募）
2 期
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesMelanomaBrain MetastasesNCT02374242Melanoma Institute Australia76
终止
2 期
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaRelapsed Multiple MyelomaRefractory Multiple MyelomaNCT04119336Andrew Yee, MD2
进行中（未招募）
2 期
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.Esophageal Squamous Cell CarcinomaNCT04229459Baruch Brenner12
进行中（未招募）
2 期
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerKidney CancerAdvanced Renal Cell CarcinomaClear Cell Renal Cell CarcinomaNCT05239533Memorial Sloan Kettering Cancer Center9
已完成
2 期
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)Pan TumorNCT03668119Bristol-Myers Squibb212
相关资讯
KEYNOTE-B61 Demonstrates Robust Data for Non-Clear Cell Renal Cell Carcinoma Treatment- The KEYNOTE-B61 trial, investigating pembrolizumab plus lenvatinib, shows more robust data than the CA-209 9KU trial for non-clear cell renal cell carcinoma (non-ccRCC).
- KEYNOTE-B61 enrolled 158 patients with various non-ccRCC subtypes, reporting a median PFS of 18 months, providing more reliable findings due to its larger sample size.
- While nivolumab plus cabozantinib remains a viable option, KEYNOTE-B61's pembrolizumab plus lenvatinib has emerged as a preferred treatment for many oncologists treating non-ccRCC.
- Cross-trial comparisons are unreliable due to differences in baseline patient populations, but KEYNOTE-B61 offers narrow confidence intervals and broader representation of histologic subtypes.last yearIO/TKI Combinations Show Promise in Non-Clear Cell Renal Cell Carcinoma- Pembrolizumab plus lenvatinib demonstrated a 50% overall response rate in treatment-naive non-clear cell RCC, leading to FDA approval and NCCN recommendation.
- Cabozantinib plus nivolumab showed a 54% overall response rate in a phase 2 trial, supporting its use in non-clear cell RCC, even with prior therapy in some patients.
- Both IO/TKI combinations exhibit manageable adverse event profiles, with common toxicities including hypertension, diarrhea, and hand-foot syndrome.
- Dose adjustments and interruptions are crucial for managing toxicities and maintaining patients on treatment, potentially improving long-term outcomes.last yearIO/TKI Doublets Emerge as Standard of Care in Non-Clear Cell Renal Cell Carcinoma- Phase 2 trials show that IO/TKI combinations, like lenvatinib plus pembrolizumab, demonstrate efficacy in non-clear cell renal cell carcinoma (non-ccRCC) with manageable safety profiles.
- KEYNOTE-B61 trial reported a 51% objective response rate (ORR) in non-ccRCC patients treated with lenvatinib and pembrolizumab, supporting NCCN guideline recommendations.
- Cabozantinib plus nivolumab also shows promise, with a 48% ORR in a phase 2 trial, establishing IO/TKI doublets as effective first-line options for non-ccRCC.
- Treatment decisions should consider patient preference and individual data interpretation, according to Dr. Moshe Ornstein from Cleveland Clinic.2 years ago